Niki BioSolutions(NASDAQ) NIKI

Market Cap$5.62M

Since IPO (2018)-95%

5 Year-97%

1 Year-65%

1 Month-31%

$7.15

+3.62%

+0.25Today

After hours$7.07-$0.08 (-1.12%)

Niki BioSolutions last closing stock price
Metric	Price	Date
Last close	USD 6.86	2026-08-31

Niki BioSolutions stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-14.36%	USD 8.01	2026-08-24
1 month	-30.5%	USD 9.87	2026-07-31
3 month	-29.71%	USD 9.76	2026-06-02
Year to date	-35.28%	USD 10.60	2025-12-31
1 year	-65.18%	USD 19.70	2025-08-29
3 year	-69.38%	USD 22.40	2023-09-01
5 year	-97.39%	USD 263.00	2021-09-01
Since inception	-95.19%	USD 143.50	2018-12-18

Niki BioSolutions Financials at a Glance

Market Cap

$5.62M

Revenue (TTM)

$0.00

Net Income (TTM)

-$2.28M

EPS (TTM)

-$3.52

P/E Ratio

-1.96

Dividend

$0.00

Beta (Volatility)

0.66 (Low)

Dividend

$0.00

Beta (Volatility)

0.66 (Low)

Price

$7.15

Volume

94,803.496

Open

$6.69

Price

$7.15

Volume

94,803.496

Open

$6.69

Previous Close

$6.86

Daily Range

$6.55 - $7.15

52-Week Range

$6.00 - $25.90

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

0.66 (Low)

Price

$7.15

Volume

94,803.496

Open

$6.69

Previous Close

$6.86

Daily Range

$6.55 - $7.15

52-Week Range

$6.00 - $25.90

Estimated Earnings Date

N/A

NIKI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Niki BioSolutions

Niki BioSolutions, Inc. is a biopharmaceutical company formed from the merger of Aptorum Group and DiamiR Biosciences. The company is dedicated to developing and commercializing a diverse range of therapeutic and diagnostic assets, focusing on unmet medical needs in oncology and infectious diseases.

Products and Services

Innovative treatments for oncology and infectious diseases
Blood-based diagnostic tests for brain health
Development of therapeutic assets targeting unmet medical needs

Growth Outlook

Market potential in oncology and infectious diseases is significant
Focus on innovative diagnostics aligns with healthcare trends
Strong pipeline of therapeutic assets supports future growth

Financial Highlights

Recent quarterly net income of -$307,495 reflects ongoing investment in R&D
Cash and short-term investments totaled $3,452,891 as of Q4 2025
Trailing twelve months (TTM) cash flow indicates a strategic focus on growth despite losses

Niki BioSolutions, Inc. operates in a dynamic biotechnology sector, addressing critical healthcare challenges. The company's commitment to innovation is evident in its diverse product offerings, which aim to meet significant medical needs. The growth outlook remains promising, driven by a strong pipeline and alignment with current healthcare trends. Financially, while the company is currently operating at a loss, it maintains a solid cash position, allowing for continued investment in research and development. This strategic focus on innovation and market needs positions Niki BioSolutions as a noteworthy player in the biopharmaceutical landscape.

AI Generated • Aug 24, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Ian Huen, CFA

Website

www.aptorumgroup.com

Headquarters

Princeton, NJ 08540, US

NIKI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-5.94%

Return on Capital

-6.83%

Return on Assets

-7.29%

Earnings Yield

-51.02%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.62M

Shares Outstanding

814.40K

Volume

94.80K

Avg. Volume

90.12K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$402.77K

EBITDA

-$1.54M

Operating Cash Flow

-$3.26M

Capital Expenditure

-$48.00

Free Cash Flow

-$3.26M

Cash & ST Invst.

$3.45M

Total Debt

$3.44M

Niki BioSolutions Performance Analysis

Niki BioSolutions annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 1,295,889	-15.9%
2023	2023-12-31	USD 431,378	-66.7%
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Niki BioSolutions sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-12-31	N/A
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A

Niki BioSolutions annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -27.45	-61.6%
2023	2023-12-31	USD -6.25	-77.2%
2024	2024-12-31	USD -7.83	25.3%
2025	2025-12-31	USD -1.85	-76.3%

Niki BioSolutions sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2024-12-31	N/A
Q2	2025-06-30	N/A
Q3	2025-09-30	-37.1%
Q4	2025-12-31	50.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$5.62M

N/A

Market Cap/Employee

$5.62M

N/A

Employees

N/A

Net Income

-$307.50K

+88.4%

EBITDA

-$825.13K

+64.7%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

$3.45M

+340.9%

Total Debt

$3.44M

+1.9%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$3.44M

+1237.2%

Return on Assets

-7.29%

N/A

Return on Invested Capital

-2.86%

N/A

Free Cash Flow

-$535.26K

+91.4%

Operating Cash Flow

-$535.26K

+91.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About NIKI

What is the current price of Niki BioSolutions?

Niki BioSolutions is trading at $6.86 per share.

What is the 52-week range for Niki BioSolutions?

Over the past 52 weeks, Niki BioSolutions has traded between $6.00 and $25.90.

How much debt does Niki BioSolutions have?

As of the most recent reporting period, Niki BioSolutions reported total debt of $3.52M.

How much cash does Niki BioSolutions have on hand?

Niki BioSolutions reported $3.45M in cash and cash equivalents in its most recent financial results.

What is Niki BioSolutions’s dividend yield?

Niki BioSolutions does not currently have a dividend yield.

Niki BioSolutions(NASDAQ) NIKI

Niki BioSolutions Financials at a Glance

NIKI News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Niki BioSolutions

NIKI Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Niki BioSolutions Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NIKI

What is the current price of Niki BioSolutions?

What is the 52-week range for Niki BioSolutions?

How much debt does Niki BioSolutions have?

How much cash does Niki BioSolutions have on hand?

What is Niki BioSolutions’s dividend yield?

Premium Investing Services